Immunotherapy has revolutionized the oncology landscape. However, resistance remains a significant hurdle in gastric cancer treatment. A new study introduces a machine learning model to predict gastric cancer immunotherapy response. This model utilizes single-cell transcriptomics to identify specific cellular determinants of resistance.

The research identifies a unique T/NK cell subset associated with poor outcomes. These cells exhibit impaired MHC-I-mediated immune recognition. Furthermore, they display elevated histidine metabolism and stay at an early differentiation stage. Consequently, these findings offer a new map of the tumor microenvironment. Understanding these cell populations is crucial for refining treatment protocols.

Improving Gastric Cancer Immunotherapy Response with IRF1

The study highlights the transcription factor IRF1 as a potential suppressor of resistance. Mechanistically, IRF1 inhibits invasion and promotes cancer cell death through apoptosis. Additionally, the developed machine learning model predicts patient responses accurately across two independent cohorts. Notably, the model achieved AUCs of 0.75 and 0.73. Therefore, these insights may guide future personalized therapy strategies. Targeting the T/NK cell subset or restoring IRF1 function represents a promising approach to overcoming resistance.

Frequently Asked Questions

What is the role of IRF1 in gastric cancer resistance?

IRF1 acts as a suppressor of immune resistance. It works by inhibiting the invasion of cancer cells and promoting apoptosis, which enhances the effectiveness of immunotherapy.

How does the machine learning model predict treatment outcomes?

The model analyzes single-cell transcriptomic data to identify T/NK cell subsets and metabolic markers. It reached predictive accuracy with AUCs of 0.75 and 0.73 in independent patient groups.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Ning W et al. A Single-Cell Guided Machine Learning Model Predicts Response to Immune Checkpoint Inhibitors in Gastric Cancer. J Chem Inf Model. 2026 Jun 11. doi: 10.1021/acs.jcim.6c01090. PMID: 42273856.

Sun K et al. Single-cell transcriptomics in cancer immunotherapy. Journal of Hematology & Oncology. 2024;17(1):15-28.

Chen W et al. IRF1 suppresses gastric tumorigenesis via dual PI3K/AKT-ERK pathway modulation. Cell Oncol (Dordr). 2026 Jan 13;49(1):24. doi: 10.1007/s13402-025-01134-w.